The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited therapy may be feasible in certain cases, particularly when combined with other targeted agents.
Taejun J. Yoon, MD
Advertisement
Articles by Taejun J. Yoon, MD
Advertisement
Latest Updated Articles
BTK Inhibitor Therapy Can Be Stopped in CLLSeptember 20th 2024
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Late-Breaking Phase 3 Data Headline ESMO 2026 Presidential Symposium I
2
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
3
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
4
Sunvozertinib Now Available in US for EGFR Exon 20 Insertion NSCLC
5